Preclinical Contract Research / In Vitro Modeling for Drug Screening, Disease Modeling & Microbiome Research – CRO
Altis Biosystems is a private equity-backed biotech company that spun out of a research lab at UNC Chapel Hill. It pioneered an in vitro modeling system enabling preclinical testing that more accurately replicates human biology while reducing the need for animal testing. Altis engaged us to develop a go-to-market strategy that would build awareness for their platform.
The key challenge in the preclinical research space is to provide accurate models that optimize the changes of later success for molecules that advance. We established a go-to-market strategy for Altis Biosystems demonstrating how its proprietary in vitro platform could support researchers in bringing therapies through the clinic faster and more efficiently.
Altis Biosystems’ new branding gave the company a credible, established look in under 12 weeks, providing valuable mechanisms to funnel leads into sales. To date, Altis’s RepliGut® model is used by a number of Big Pharma companies in preclinical research across a range of pharmacological applications including inflammation, toxicity, bioavailability, and barrier function.